bluebird bio (BLUE) : The money flow analysis of bluebird bio (BLUE) indicates a $5.38 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $6.03 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.12 and so was the total money flow at $0.65 million. The bulls lapped up $0 million worth of block trades on upticks. The money flow was $0 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of bluebird bio (BLUE), pushing it down by -0.52% for the day. The stock slid $0.26 and traded at $49.08 during the day. Nonetheless, the stock is -4.21% over the previous weeks close.
The company Insiders own 3.5% of bluebird bio shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -14.9% . During last six month period, the net percent change held by insiders has seen a change of -14.9%.
In a related news, Sullivan Eric, officer (Principal Accounting Officer) of Bluebird Bio, Inc., unloaded 416 shares at an average price of $59 on August 3, 2016. The total amount of the transaction was worth $24,544, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
bluebird bio (NASDAQ:BLUE): stock was range-bound between the intraday low of $48.27 and the intraday high of $50.85 after having opened at $49.65 on Fridays session. The stock finally closed in the red at $49.65, a loss of -0.57%. The stock remained in the red for the whole trading day. The total traded volume was 468,750 shares. The stock failed to cross $50.85 in Fridays trading. The stocks closing price on Thursday was $49.33.
bluebird bio (BLUE) : During the past 4 weeks, traders have been relatively bearish on bluebird bio (BLUE), hence the stock is down -15.03% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.74% relative to the S&P 500. The 4-week change in the price of the stock is -15.14% and the stock has fallen -4.26% in the past 1 week.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.